Xencor Release: Data Published in Nature Biotechnology Shows Fc Engineering Improves Antibody Efficacy and Convenience  
1/19/2010 9:38:10 AM

Bookmark and Share

MONROVIA, Calif.--(BUSINESS WIRE)--A Nature Biotechnology article published online January 17 reveals that Xencor Inc.’s proprietary Fc engineering extends the half-life of antibodies while maintaining their potency and extending duration of action. These results, published in an article entitled, “Enhanced antibody half-life improves in vivo activity” demonstrate the potential of Fc engineering to impact the flexibility of route, schedule and dose for nearly any antibody.